Tracking Brucella abortus Infection in Immunized Mice Using In Vivo Bioluminescence Imaging.
Tarahomjoo Shirin S, Etemadi Afshar A, Alamian Saeed S
Brucella is the pathogen responsible for brucellosis, an important zoonotic illness, which affects humans and livestock worldwide. Currently, animal vaccination is used to prevent transmission of brucellosis from livestock to humans. The spread of luminous bacteria in laboratory animals can be monitored by bioluminescence imaging (BLI). In this study, therefore, we aim to develop an in vivo BLI strategy for assessing the immunogenicity of the brucellosis Rev1 vaccine, taking its benefits of shorter assay duration and reduced safety risks for the laboratory personnel. We have constructed a recombinant Brucella abortus 544 (BAPGH5) in which the firefly luciferase is expressed under the control of the PgroE promoter using the pPGH6-BSF22 plasmid. The parB locus was included in the plasmid to stabilize it in the absence of the antibiotic. The recombinant Brucella showed intense bioluminescence in vitro without using the antibiotic typically used for plasmid maintenance. It exhibited better growth compared to the parental strain. BAPGH5 showed strong bioluminescence in vivo when administered to mice intraperitoneally and colonized the mice spleens at a level comparable to that of the parental strain administered at the standard dose for the Rev1 vaccine immunogenicity testing. The recombinant Brucella isolated from the mice spleens showed strong bioluminescence, indicating in vivo stability of the pPGH6-BSF22 plasmid. The dissemination pattern of BAPGH5 in mice immunized with the Rev1 vaccine was clearly distinct from that of the control mice, as revealed by BLI. These results suggest the usefulness of the developed in vivo BLI strategy for assessing the immunogenicity of the Rev1 vaccine.